Through the advancements in glycoproteomics and artificial intelligence, the company was able to analyze archival samples at the Institute for Medical Research, National Institute of Health, Ministry of Health Malaysia to successfully identify patients with nasopharyngeal carcinoma, a type of head and neck cancer, commonly called nasal cancer. SAN FRANCISCO & KUALA LUMPUR Feb 4 (Bernama) -- InterVenn Biosciences today announced it was able to correctly predict samples from patients with nasopharyngeal cancer with 100 percent accuracy in a research study evaluating 100 samples. This was carried out in collaboration with the Institute for Medical Research, National Institutes of Health, Ministry of Health Malaysia. The samples were studied by InterVenn using their proprietary approach to analyze glycoproteins using artificial Intelligence. The collaboration was made possible through facilitation by Clinical Research Malaysia, an agency under the Ministry of Health Malaysia. InterVenn is in talks with international partners to help expedite commercialization and clinical validation of a new diagnostic for nasal cancer and other indications.
Dr. Alan Khoo, head of the Cancer Research Centre at the Institute for Medical Research, emphasized that late detection of cancer remains a major problem in many parts of the world, including Malaysia as recently revealed in the National Cancer Registry Report. Detection of cancers through blood based testing is a useful approach, this includes nasopharyngeal cancer, which is a major regional cancer affecting South East Asia and Southern China.
Glycoproteins remain the most commonly used form of blood based markers for cancer as many existing blood based cancer biomarkers lack sensitivity when used for screening. Using a highly sensitive glycoproteomics technology coupled with artificial intelligence, panels of novel glycoprotein markers which corresponds to cancers could be identified.
The approach used in this analysis is similar to the company’s on-going liquid biopsy to investigate a clinical decision-making tool for ovarian cancer. The aim is to distinguish malignant pelvic tumors from benign ones, without compromising diagnostic accuracy nor subjecting patients to undergo potentially unnecessary and harmful surgery.
“There is a very large unmet need when it comes to a single platform approach for screening and early detection of cancers which could be used across the Asian continent,” said Aldo Carrascoso, Chief Executive Officer of InterVenn Biosciences. “As of now, there are limited options for screening, and we are excited to work with the government of Malaysia and other Asian countries to advance.” Intervenn Biosciences, which has offices in the United States, Malaysia and Philippines, is changing the way the world deals with cancer and other diseases by combining mass spectrometry and artificial intelligence to unlock glycoproteomics for biomarker and target discovery.
About InterVenn BiosciencesInterVenn Biosciences utilizes a proprietary glycoproteomic biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine. For more information, please visit the company’s website at https://intervenn.bio/SOURCE: MINITA Resources FOR MORE INFORMATION, PLEASE CONTACT:Name: Andrea Vuturo
Tel: (888) 706-1670 Email:
press@venn.bio--BERNAMA 
